FBC
CCCC icon

Fairfield, Bush & Co’s C4 Therapeutics CCCC Stock Holding History

Fairfield, Bush & Co’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$1.13K – 165
2023
Q4 		$1.13K Buy
+200
New +$456 ﹤0.01% 429

Other funds holding CCCC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fairfield, Bush & Co's CCCC Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of C4 Therapeutics (CCCC) in Q1 2024, closing a stake of 200 shares — an estimated $1.13K sold.

Fairfield, Bush & Co first reported a position in CCCC in Q4 2023 and held it in 1 quarter. The position peaked at $1.13K in Q4 2023. 106 funds tracked by Wall St. Rank hold CCCC as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining C4 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 200 C4 Therapeutics shares in Q1 2024, an estimated $1.13K.
  • Fairfield, Bush & Co first reported a position in C4 Therapeutics in Q4 2023 and held it in 1 quarter.
  • Fairfield, Bush & Co's C4 Therapeutics position peaked at $1.13K in Q4 2023.
  • 106 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.